We examined the effect of changing the ratio between amino- and guanidino-functionalized cationic residues as well as the Selleck Sapanisertib influence of chain length on both antibacterial activity and ATP leakage. Although, minor differences in the antimicrobial profile of the chimeras may be ascribed to the degree of chirality and/or type of cationic amino acids, by far the most pronounced impact stems from the chain length. Only one bacterial species,
S. marcescens, was tolerant to the peptidomimetics most likely due to the composition of its outer membrane; however, the ATP leakage was as pronounced as seen for more sensitive bacteria. We conclude that these synthetic antimicrobial peptidomimetics exert their effect through permeabilization of the cell membrane, and that this corresponds to a simultaneous reduction in the number of viable bacteria with the pool of intracellular ATP being indicative of viability. This is the first time that a relationship is established between permeabilization and killing within a peptidomimetics library. Acknowledgements LHK was funded
by a Ph.D. grant from the Technical University of Denmark and the Danish Research Council for Technology and Production (grant number 09-065902/FTP). The authors wish to thank the National Center GDC 0032 cost for Antimicrobials & Infection Control, Statens Serum Institut, Denmark for providing the Danish clinical samples of ESBL-producing E. coli. We thank, the Brødrene Hartmanns Fond (Copenhagen) for a materials grant supporting the synthesis
work. References 1. Zasloff M: Antimicrobial peptides of multicellular organisms. Nature 2002, 415:389–395.PubMedCrossRef 2. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE: Impact of LL-37 on anti-infective immunity. J Leukoc Biol 2005, 77:451–459.PubMedCrossRef 3. Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003, 3:710–720.PubMedCrossRef 4. Gallo RL, Nizet V: Endogenous production of antimicrobial peptides in innate immunity and human disease. Curr Allergy Asthma Rep 2003, Bumetanide 3:402–409.PubMedCrossRef 5. Brown KL, Hancock RE: Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 2006, 18:24–30.PubMedCrossRef 6. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al.: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1–12.PubMedCrossRef 7. Fischbach MA, Walsh CT: Antibiotics for emerging pathogens. Science 2009, 325:1089–1093.PubMedCrossRef 8. Hancock RE, Sahl HG: Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006, 24:1551–1557.PubMedCrossRef 9. Chen Y, Mant CT, Farmer SW, Hancock RE, Vasil ML, Palbociclib manufacturer Hodges RS: Rational design of α-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index.